OptiNose: Maximum OptimismGood afternoon.
I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company.
Summary:
Technical analysis:
On the chart, we can see the completion of corrective wave 2 and the emergence of impulse wave 3.
According to the RSI indicator, we can see an uptrend, which confirms the labeling of the Elliott waves.
On the 1D chart, we can see an open gap in the area of $6-7 per share.
Currently, the company's shares are in the area of the downtrend breakout. In addition, Optinose shares have broken through EMA 55 and are just below EMA 89.
Fundamental Analysis:
You can read a complete fundamental analysis of the company in my analytical article in SA.
Conclusion
Considering the above factors, I believe that the growth of Optinose shares will continue.
Disclosure:
This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sold securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.
Optinose
OPTINOSE: "Rocket launch"Greetings
Summary:
Fundamental Analysis:
Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019
Company expects top-line results from one of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis by the end of 2021
In April 2021, the Company expects to initiate a randomized, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms. This pilot study being conducted in Mexico will evaluate both the magnitude and duration of viral load reduction after a single dose of OPN-019. The Company expects top-line results from this study in second quarter 2021.
The company shows stable revenue growth from year to year.
Technical analysis:
From May 2020 to the end of June 2020, the 5th wave movement was completed.After that, a correction began.
At the moment, the company's shares are in the oversold zone according to the RSI indicator.
The company has several open gaps, namely in the following areas: $ 6-7, $ 10-11 per share.
At the moment, the company's shares are at a strong support level .
Disclosure: I am/we are long OPTN.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from TradingView). I have no business relationship with any company whose stock is mentioned in this article.